Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Obesity
Acute Ischemic Stroke (AIS)
Hypertension
Our expertise
Overview
Our strategic partners
Global opportunities
Join us
Press releases
Contact
简体中文
Search
简体中文
Navigation
Press releases
19 Nov 2021
JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China
Read article
05 Aug 2021
Oyster Point Pharma Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China
Read article
13 Jul 2021
RTW Investments-Backed JIXING Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer
Read article
17 May 2021
Milestone Pharmaceuticals Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
Read article
14 Jul 2020
RTW Investments, LP, JIXING Pharmaceuticals and Cytokinetics Enter into Strategic Financing Collaboration to Support the Development of CK-274 and Enter China
Read article
